Clinical considerations for the design of PROTACs in cancer

Degradation of targeted proteins using proteolysis targeting chimeras (PROTACs) has gained momentum. A PROTAC is a bifunctional molecule that consists of three parts: a ligand that interacts with the protein to be degraded, another ligand that binds to an E3 ubiquitin ligase and a linker that connec...

Descripción completa

Detalles Bibliográficos
Autores principales: Nieto-Jiménez, Cristina, Morafraile, Esther Cabañas, Alonso-Moreno, Carlos, Ocaña, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900451/
https://www.ncbi.nlm.nih.gov/pubmed/35249548
http://dx.doi.org/10.1186/s12943-022-01535-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900451/
https://www.ncbi.nlm.nih.gov/pubmed/35249548
http://dx.doi.org/10.1186/s12943-022-01535-7

Ejemplares similares